Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.250
-0.090 (-2.07%)
At close: Sep 11, 2026, 4:00 PM EDT
4.590
+0.340 (8.00%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Camp4 Therapeutics Employees
Camp4 Therapeutics had 48 employees as of December 31, 2025. The number of employees decreased by 7 or -12.73% compared to the previous year.
Employees
48
Change (1Y)
-7
Growth (1Y)
-12.73%
Revenue / Employee
$87,833
Profits / Employee
-$2,234,250
Market Cap
266.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 48 | -7 | -12.73% |
| Dec 31, 2024 | 55 | -9 | -14.06% |
| Sep 30, 2024 | 53 | -11 | -17.19% |
| Jun 30, 2024 | 58 | - | - |
| Dec 31, 2023 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Bicycle Therapeutics | 288 |
| ProQR Therapeutics | 187 |
| Fate Therapeutics | 161 |
| Sutro Biopharma | 128 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Lineage Cell Therapeutics | 77 |
CAMP News
- 3 days ago - CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder - GlobeNewsWire
- 4 days ago - Camp4 Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 days ago - CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 - GlobeNewsWire
- 12 days ago - CAMP4 to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c) - TheFly
- 4 weeks ago - Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler - TheFly
- 4 weeks ago - CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Camp4 Therapeutics Quarterly report: Q2 2026 - Filings